Lexicon Pharmaceuticals
LXRX
119 hedge funds and large institutions have $1.15B invested in Lexicon Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 33 increasing their positions, 41 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1.31% less ownership
Funds ownership: 102.84% → 101.53% (-1.3%)
2% less funds holding
Funds holding: 121 → 119 (-2)
11% less capital invested
Capital invested by funds: $1.29B → $1.15B (-$143M)
20% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 41
22% less call options, than puts
Call options by funds: $3.33M | Put options by funds: $4.29M
Top Buyers
| 1 |
ClearBridge Investments
New York
|
+$14.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.07M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.89M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$1.64M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.57M |
Top Sellers
| 1 |
Marshall Wace
London,
United Kingdom
|
-$7.06M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.25M |
| 3 |
Millennium Management
New York
|
-$3.97M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.93M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$1.96M |
LXRX Hedge Fund Activity: Q3 2018 in Review
119 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2018, worth a combined $1.15B — down 11% from $1.29B a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of LXRX and 12 opened new positions — a net loss of 1 holder — while 41 trimmed existing stakes and 33 added.
The largest buyer was ClearBridge Investments, adding an estimated $14.8M. The largest seller was Marshall Wace, cutting an estimated $7.06M.
- 119 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2018, down from 121 in Q2 2018.
- Funds reported $1.15B of Lexicon Pharmaceuticals stock for Q3 2018, down 11% quarter-over-quarter.
- 12 funds opened new Lexicon Pharmaceuticals positions in Q3 2018 and 13 closed out, a net change of -1 holder.
- The largest Lexicon Pharmaceuticals buyer in Q3 2018 was ClearBridge Investments, an estimated $14.8M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2018 was Marshall Wace, an estimated $7.06M sold.
Based on aggregated 13F filings for Q3 2018.